Template:Ergotamine: Difference between revisions

Jump to navigation Jump to search
(Blanked the page)
No edit summary
Line 1: Line 1:
 
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[ERGOMAR (ergotamine tartrate) tablet|{{fontcolor|#6C7B8B|ERGOMAR (ergotamine tartrate) tablet}}]]'''''
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ERGOMAR (ergotamine tartrate) tablet<sup>®</sup> FDA Package Insert
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet indications and usage|Indications and Usage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet dosage forms and strengths|Dosage Forms and Strengths]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet contraindications|Contraindications]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet warnings and precautions|Warnings and Precautions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet adverse reactions|Adverse Reactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet use in specific populations|Use in Specific Populations]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet description|Description]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet clinical studies|Clinical Studies]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet patient counseling information|Patient Counseling Information]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ERGOMAR (ergotamine tartrate) tablet labels and packages|Labels and Packages]]
|-
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[ERGOMAR (ergotamine tartrate) tablet|{{fontcolor|#6C7B8B|ERGOMAR (ergotamine tartrate) tablet}}]]'''''
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ZZZZZ<sup>®</sup> FDA Package Insert
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX indications and usage|Indications and Usage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX dosage forms and strengths|Dosage Forms and Strengths]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX contraindications|Contraindications]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX warnings and precautions|Warnings and Precautions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX adverse reactions|Adverse Reactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX use in specific populations|Use in Specific Populations]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX description|Description]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX clinical studies|Clinical Studies]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX patient counseling information|Patient Counseling Information]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[XXXXX labels and packages|Labels and Packages]]
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on XXXXX
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
|-
|}

Revision as of 22:53, 11 February 2014